TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology
SEATTLE, April 24, 2024 /PRNewswire/ — TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from genetic toxicology to residual cancer detection announces the successful acceptance of the standard project submission form (SPSF) by the Organization for Economic Cooperation and Development (OECD). This significant milestone will accelerate commencement of the global regulatory acceptance process for error-corrected Next Generation Sequencing (ecNGS) for mutagenesis testing.
Ultrasensitive Circulating Tumor DNA Improves NSCLC Detection
JUN 13, 2024 Ultrasensitive circulating tumor DNA (ctDNA) detection appears to improve the clinical sensitivity of minimal residual disease (MRD) at key landmarks in early stage non-small cell lung cancer (NSCLC), researchers reported at the 2024 ASCO Annual Meeting. “PhasED-Seq detected MRD at levels below one ppm and was associated with significantly better outcomes, revealing potential benefits […]
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
AGC Biologics Doubles Single-Use Bioreactor Capacity with Expansion at Denmark Site
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
Upkara seeks partnerships for breakthrough biomolecule stabilization technology under leadership of new CEO
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
AGC Biologics Announces Successful Completion of Production of Cancer-Specific Therapeutic Antibody Fragments with Var2 Pharmaceuticals
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
TwinStrand Biosciences Initiates Regulatory Approval Process for Duplex Sequencing Mutagenesis Assays with OECD
SEATTLE, April 24, 2024 /PRNewswire/ — TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from genetic toxicology to residual cancer detection announces the successful acceptance of the standard project submission form (SPSF) by the Organization for Economic Cooperation and Development (OECD). This significant milestone will accelerate commencement of the global regulatory acceptance process for error-corrected Next Generation Sequencing (ecNGS) for mutagenesis testing.
Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board
SAN JOSE, Calif.–(BUSINESS WIRE)–Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB). The Nodexus SAB is chaired by Professor Jonni Moore, PhD, one of the world’s leading experts in flow cytometry, laboratory medicine, and cellular immunology.
Ultivue Announces its STARVUE™ Image Data Science Platform, Providing Researchers with an Integrated, AI-Driven Analytical Solution for Generating Spatial Insights
CAMBRIDGE, Mass., April 3, 2024 /PRNewswire/ — Ultivue, a market leader in quantitative proteomic biomarker detection and advanced spatial tissue profiling, is unveiling its spatial insights platform, STARVUE™, at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10 in San Diego, CA. STARVUE™ is the culmination of Ultivue’s multi-year engineering efforts to bring the latest innovations in artificial intelligence and image data science to translational and clinical research applications, via a highly accurate and scalable analytical solution.
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
SECAUCUS, N.J., April 2, 2024 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
